CClinicalTrials.gg
RecruitingNCT06706583TELÉMACOUpdated Nov 26, 2024

Clinical and Ecological Impact of a Primary Care Antimicrobial Stewardship Program Based on Telematic Educational Interviews (TELÉMACO Trial)

An interventional study of Telematic educational interviews + standard training and Standard training in Community Acquired Infections, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Sex
All
01

Study summary

Brief Summary: Open-label, cluster randomized, multicenter clinical trial to evaluate the clinical and ecological impact of a Primary Care ASP based on telematic educational interviews.

Read the detailed description

The objective of this project is to measure the effect of an Antimicrobial Stewardship Program (ASP) in Primary Care, based on an educational intervention.

This will consist of periodic structured telematic educational interviews between Infectious Diseases experts and Family Medicine and paediatrics specialists. In these interviews, the principles for the optimal use of antimicrobials will be addressed on real cases, analyzing together prescriptions randomly chosen from the Primary Care physician himself.

The repetition over time of key pedagogical messages for the optimisation of prescriptions is expected to improve the quality of antibiotic use, reduce the overall consumption, improve the use of microbiological tests, reduce the incidence of community infections caused by resistant microorganisms, and preserve patients' safety measured by the rate of admission for serious infections.

The results derived from these educational interventions, in the framework of a multimodal ASP, have been evaluated in hospital and Primary Care settings in quasi-experimental studies with a favourable outcome, but not in a clinical trial that specifically assesses the efficacy of educational interviews and avoids the bias of uncontrolled studies. To demonstrate this hypothesis, a cluster randomized trial has been designed, in wich all healthcare centers will be assigned either to a control group (the standard measures defined by the regional ASP PIRASOA will be maintained), and an experimental group (whose physicians will receive the educational intervention described).

02

Conditions studied

  • Community Acquired Infections

Keywords

  • Antimicrobial Stewardship Program (ASP)
  • Primary Care
  • Telemedicine
  • PIRASOA
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

a) Primary Care centres within the reference area of the University Hospital Virgen del Rocío.

Exclusion criteria

Exclusion criteria:

  1. Emergency departments.
  2. Odontology offices.
  3. DDD per Health centre less than 5.78
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Enhanced education arm

    Telematic educational interviews are added to standard PIRASOA training

    Behavioral: Telematic educational interviews + standard training

  • Active comparator
    Standard education arm

    Only standard PIRASOA training is provided

    Behavioral: Standard training

Interventions

  • BehavioralTelematic educational interviews + standard training

    Physicians attending at healthcare centers in the experimental arm will receive periodic telematic educational interviews in which an Infectious Diseases consultant will provide practical training on the appropriate use of antibiotics through the review of one of the physician´s randomly chosen antibiotic prescription, according to a structured brief interview. In addition to this, each of these centres will continue carrying out the already established activities of the Regional ASP (PIRASOA).

  • BehavioralStandard training

    Primary Care Health Centers assigned to the control group will receive standard educational activities designated by the current Regional ASP (PIRASOA).

05

What researchers measure

Primary outcomes

  1. Total antimicrobial consumption

    Total antimicrobial antimicrobial will be measured using the recommended international standard, the Defined Daily Dose (DDD) per 1000 inhabitants per day. Predefined subgroup analyses will be conducted to assess the intervention\'s effect on the primary outcome based on: patient age, geneder, and socioeconomic level.

    Time frame: Monthly over a 36-month period

Secondary outcomes

  1. Adequacy of antimicrobial prescriptions

    The rate of appropriate antimicrobial prescriptions according to national reference guidelines will be assessed through three point prevalence surveys of randomly selected prescriptions.

    Time frame: Prevalence surveys will be performed at months +0, +7 and +15.

  2. Incidence density of hospitalizations due to infections

    The incidence density of hospitalizations due to infections (urinary, pneumonia and skin and soft tissue infections), and specifically due to Clostridiodes difficile infections per inhabitant.

    Time frame: Monthly, over a 36-month period.

  3. Incidence density of resistant Enterobacterales in urine cultures

    Incidence density of resistant Enterobacterales in urine cultures per inhabitant sent from Primary Care centers from both arms.

    Time frame: Monthly, over a 36-month period.

06

Study locations

1 of 1 sites recruiting
  • Hospital Universitario Virgen del Rocío
    Sevilla, 41013, Spain
    • Jose Molina Gil-Bermejo, MD-PhD · Contact · josemolinagb@gmail.com
    • Jose Molina Gil-Bermejo · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06706583
Lead sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Nov 26, 2024

Study contacts

Clara M Rosso Fernández, MD-PhD
Contact
claram.rosso.sspa@juntadeandalucia.es
+34955013414
Jose Molina Gil-Bermejo, MD-PhD
Contact
josemolinagb@gmail.com
José Miguel Cisneros Herreros, MD-PhD
study director · Hospitales Universitarios Virgen del Rocío

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion